•
AP
APRE
Aprea Therapeutics, Inc. Common stock
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
6.12M
Volume
97.96K
52W High
$4.65
52W Low
$0.83
Open
$0.87
Prev Close
$0.88
Day Range
0.83 - 0.91
About Aprea Therapeutics, Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Latest News
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
GlobeNewswire Inc.•Jun 25
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
GlobeNewswire Inc.•May 14
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
GlobeNewswire Inc.•Jun 21
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
GlobeNewswire Inc.•Jun 17
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
GlobeNewswire Inc.•May 28
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
GlobeNewswire Inc.•May 13
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•May 2
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
GlobeNewswire Inc.•Apr 10